Role of TP53 Mutations and EGFR Amplification in Risk Stratification of Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer With Immunohistochemistry as a Surrogate Marker
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Specific TP53 mutations and EGFR amplification predict poor outcomes in early-stage non-small cell lung cancer (NSCLC). Immunohistochemistry (IHC) can identify these high-risk patients for targeted therapy.
Area Of Science
- Oncology
- Molecular Biology
- Cancer Genetics
Background
- Non-small cell lung cancer (NSCLC) is a major cause of cancer mortality.
- Early-stage NSCLC recurrence poses treatment challenges.
- The prognostic role of concurrent genetic alterations in EGFR-mutated NSCLC is not well-defined.
Purpose Of The Study
- To investigate the prognostic significance of TP53 mutations and EGFR amplification in early-stage NSCLC.
- To evaluate the utility of immunohistochemistry (IHC) as a surrogate for genetic testing.
Main Methods
- Retrospective analysis of 424 EGFR-mutated NSCLC patients.
- Next-generation sequencing (NGS) for genetic alterations.
- Immunohistochemistry (IHC) for TP53 and EGFR protein expression.
- Kaplan-Meier and Cox regression for survival analysis.
Main Results
- TP53 mutations and EGFR amplification were more frequent in advanced stages.
- In Stage 1 NSCLC, TP53 mutations (exon 4, frameshift/nonsense) and EGFR amplification correlated with worse overall survival (OS) and disease-free survival (DFS).
- IHC cutoffs for TP53 (15%) and EGFR amplification (H-score ≥180) showed high predictive accuracy (AUC=0.981 and 0.936).
Conclusions
- Specific TP53 mutations and EGFR amplification are significant prognostic markers in early-stage NSCLC.
- IHC serves as a practical method for risk stratification and guiding adjuvant therapy.
- Further validation studies are recommended.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
